Globally, Duchenne is the most prevalent form of muscular dystrophy in children. It primarily affects boys, and it is estimated to occur in approximately one in every 3,500 to 5,000 live male births ...

Shares of Sarepta Therapeutics have plunged again after the drugmaker reported a second death in connection with its gene therapy for muscular dystrophy FILE - The U.S. Food and Drug ...

Delandistrogene Moxeparvovec Gene Therapy in Individuals With Duchenne Muscular Dystrophy: Evidence in Focus. Neurology, 2025; 104 (11) DOI: 10.1212/WNL.0000000000213604 ...

Duchenne Muscular Dystrophy: diagnosis, clinical development and global research Muscular dystrophy refers to a group of rare, genetic, progressive diseases that primarily affect the body’s muscles, ...

Global Duchenne Muscular Dystrophy Drugs Market value attained USD 3.9 Billion in 2025. The market will achieve USD 6.5 Billion during 2034 with a growth rate (CAGR) of 10.96% during the forecast ...

Duchenne muscular dystrophy (DMD) is a disorder that causes progressive muscle weakness and a loss of function. The symptoms appear early in life, and most affected individuals require the use of ...

Amid readouts from the Muscular Dystrophy Association’s annual meeting, the Clinical Trials Arena evaluates five DMD trials to keep an eye on in 2025.

Symptoms of Duchenne Muscular Dystrophy DMD symptoms usually start by age 6. Symptoms may begin as early as infancy, but most boys don't have any symptoms in the first few years of their life.

Muscular dystrophy is a disease caused by mutations in the dystrophin gene. The muscles of muscular dystrophy patients weaken and atrophy over time. Heart and breathing muscles may also eventually be ...

The Bottom Line “Our research study of patients with Duchenne muscular dystrophy (DMD) employed both pediatric and adult hospitals. In addition to accounting for geographical variations, our ...

This year’s top stories on Duchenne muscular dystrophy (DMD) managed care included a novel imaging method for tracking disease progression, an FDA approval of the first nonsteroidal therapy, and ...